Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

622 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer.
Nishioka N, Naito T, Miyawaki T, Yabe M, Doshita K, Kodama H, Miyawaki E, Iida Y, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takayama K, Takahashi T. Nishioka N, et al. Among authors: miyawaki e, miyawaki t. Thorac Cancer. 2022 May;13(10):1496-1504. doi: 10.1111/1759-7714.14421. Epub 2022 Apr 14. Thorac Cancer. 2022. PMID: 35420262 Free PMC article.
Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
Miyawaki T, Kenmotsu H, Mori K, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Harada H, Endo M, Ohde Y, Takahashi K, Takahashi T. Miyawaki T, et al. Among authors: miyawaki e. Clin Lung Cancer. 2020 Sep;21(5):e405-e414. doi: 10.1016/j.cllc.2020.02.012. Epub 2020 Feb 26. Clin Lung Cancer. 2020. PMID: 32205040 Clinical Trial.
Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
Kodama H, Wakuda K, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T. Kodama H, et al. Among authors: miyawaki e, miyawaki t. Invest New Drugs. 2021 Apr;39(2):571-577. doi: 10.1007/s10637-020-01005-1. Epub 2020 Sep 21. Invest New Drugs. 2021. PMID: 32955628
Proposing synchronous oligometastatic non-small-cell lung cancer based on progression after first-line systemic therapy.
Miyawaki T, Wakuda K, Kenmotsu H, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ono A, Naito T, Murakami H, Notsu A, Mori K, Harada H, Endo M, Ohde Y, Takahashi K, Takahashi T. Miyawaki T, et al. Among authors: miyawaki e. Cancer Sci. 2021 Jan;112(1):359-368. doi: 10.1111/cas.14707. Epub 2020 Nov 11. Cancer Sci. 2021. PMID: 33098119 Free PMC article.
Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
Wakuda K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Harada H, Endo M, Gon Y, Takahashi T. Wakuda K, et al. Among authors: miyawaki e, miyawaki t. Lung Cancer. 2021 Jan;151:60-68. doi: 10.1016/j.lungcan.2020.11.009. Epub 2020 Nov 15. Lung Cancer. 2021. PMID: 33246646
Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer.
Nishioka N, Naito T, Notsu A, Mori K, Kodama H, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takayama K, Takahashi T. Nishioka N, et al. Among authors: miyawaki e, miyawaki t. Cancer Med. 2021 Jan;10(1):247-256. doi: 10.1002/cam4.3631. Epub 2020 Dec 10. Cancer Med. 2021. PMID: 33300678 Free PMC article.
Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.
Mamesaya N, Muramatsu K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Murakami H, Harada H, Sugino T, Shimizu T, Gon Y, Takahashi T. Mamesaya N, et al. Among authors: miyawaki e, miyawaki t. Int J Clin Oncol. 2021 Apr;26(4):659-669. doi: 10.1007/s10147-020-01856-x. Epub 2021 Jan 7. Int J Clin Oncol. 2021. PMID: 33415571
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
Miyawaki T, Kenmotsu H, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Deguchi S, Mitsuya K, Naito T, Murakami H, Mori K, Harada H, Hayashi N, Takahashi K, Takahashi T. Miyawaki T, et al. Among authors: miyawaki e. Invest New Drugs. 2021 Dec;39(6):1732-1741. doi: 10.1007/s10637-021-01140-3. Epub 2021 Jul 14. Invest New Drugs. 2021. PMID: 34259953
Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.
Omori S, Muramatsu K, Kawata T, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Wakuda K, Ono A, Kenmotsu H, Naito T, Murakami H, Sugino T, Takahashi T. Omori S, et al. Among authors: miyawaki e, miyawaki t. J Cancer Res Clin Oncol. 2022 Sep;148(9):2455-2463. doi: 10.1007/s00432-021-03784-3. Epub 2021 Sep 17. J Cancer Res Clin Oncol. 2022. PMID: 34533624
622 results